I Mahé1,2, H Puget3, J C Buzzi4, M Lamuraglia3, J Chidiac3, A Strukov4, Hélène Helfer3, A Perozziello4. 1. Hôpital Louis-Mourier, Service de Médecine Interne (APHP), Paris 7 University, 92700, Colombes, France. Isabelle.mahe@aphp.fr. 2. EA 7334 Recherche Clinique, Coordonnée Ville-Hôpital, Méthodologies et Société (REMES), Paris Diderot, Sorbonne Paris Cite, Paris, France. Isabelle.mahe@aphp.fr. 3. Hôpital Louis-Mourier, Service de Médecine Interne (APHP), Paris 7 University, 92700, Colombes, France. 4. Hôpital Bichat, Medical Information Systems Program (PMSI), APHP, University Paris 7, Paris, France.
Abstract
PURPOSE: French 2008 treatment guidelines recommend low-molecular-weight heparins (LMWH) for the treatment of cancer-associated thrombosis (CAT) with treatment duration of at least 3 months and up to 6 months and beyond if cancer remains active. Our aim was to assess adherence to guidelines in hospital clinical practice. METHODS: The French hospital database (PMSI) was used to identify patients with CAT admitted to three hospitals of the Paris region to be included in a retrospective cohort study. Adherence to guidelines was assessed in patients included from different treatment periods following the venous thromboembolism (VTE) episode i.e. first 10 days (T1), day 10 to 3 months (T2), months 3 to 6 (T3) and beyond 6 months (T4) when applicable. RESULTS: A total of 240 patients with CAT were included from January 2012 to December 2012 of whom 204 were analyzable. Treatment was adherent to guidelines in 55, 31 and 34 % of patients in T1, T2 and T3 treatment periods, respectively, while overall treatment adherence was found in 52 % of patients. Adherence rates were the highest among patients with pulmonary embolism (PE, 60.5 %), catheter-related thrombosis (62.5 %), class III/IV extended cancer (58.0 %) and metastatic malignancy (60.3 %) while only 40 % with deep vein thrombosis (DVT) received a treatment consistent with guidelines. CONCLUSION: Adherence to guidelines appears insufficient since only half of patients received an appropriate treatment. Adherence dropped significantly across treatment periods T2 and T3. VTE diagnosis and cancer characteristics influenced the anticoagulant prescription. Management of patients with CAT requires further education and information of health care professionals.
PURPOSE: French 2008 treatment guidelines recommend low-molecular-weight heparins (LMWH) for the treatment of cancer-associated thrombosis (CAT) with treatment duration of at least 3 months and up to 6 months and beyond if cancer remains active. Our aim was to assess adherence to guidelines in hospital clinical practice. METHODS: The French hospital database (PMSI) was used to identify patients with CAT admitted to three hospitals of the Paris region to be included in a retrospective cohort study. Adherence to guidelines was assessed in patients included from different treatment periods following the venous thromboembolism (VTE) episode i.e. first 10 days (T1), day 10 to 3 months (T2), months 3 to 6 (T3) and beyond 6 months (T4) when applicable. RESULTS: A total of 240 patients with CAT were included from January 2012 to December 2012 of whom 204 were analyzable. Treatment was adherent to guidelines in 55, 31 and 34 % of patients in T1, T2 and T3 treatment periods, respectively, while overall treatment adherence was found in 52 % of patients. Adherence rates were the highest among patients with pulmonary embolism (PE, 60.5 %), catheter-related thrombosis (62.5 %), class III/IV extended cancer (58.0 %) and metastatic malignancy (60.3 %) while only 40 % with deep vein thrombosis (DVT) received a treatment consistent with guidelines. CONCLUSION: Adherence to guidelines appears insufficient since only half of patients received an appropriate treatment. Adherence dropped significantly across treatment periods T2 and T3. VTE diagnosis and cancer characteristics influenced the anticoagulant prescription. Management of patients with CAT requires further education and information of health care professionals.
Authors: Javier Trujillo-Santos; José Antonio Nieto; Angeles Ruíz-Gamietea; Luciano López-Jiménez; Ferran García-Bragado; Roberto Quintavalla; Manuel Monreal Journal: Thromb Res Date: 2010-04 Impact factor: 3.944
Authors: N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm Journal: Medicine (Baltimore) Date: 1999-09 Impact factor: 1.889
Authors: Thomas Delate; Daniel M Witt; Debra Ritzwoller; Jane C Weeks; Lawrence Kushi; Mark C Hornbrook; Erin J Aiello Bowles; Deborah Schrag Journal: Oncologist Date: 2012-02-14
Authors: D Spirk; J Ugi; W Korte; M Husmann; D Hayoz; T Baldi; B Frauchiger; M Banyai; D Aujesky; I Baumgartner; N Kucher Journal: Thromb Haemost Date: 2011-04-07 Impact factor: 5.249
Authors: D Farge; P Debourdeau; M Beckers; C Baglin; R M Bauersachs; B Brenner; D Brilhante; A Falanga; G T Gerotzafias; N Haim; A K Kakkar; A A Khorana; R Lecumberri; M Mandala; M Marty; M Monreal; S A Mousa; S Noble; I Pabinger; P Prandoni; M H Prins; M H Qari; M B Streiff; K Syrigos; H Bounameaux; H R Büller Journal: J Thromb Haemost Date: 2013-01 Impact factor: 5.824
Authors: P Jimenez-Fonseca; A Carmona-Bayonas; C Calderon; J Fontcuberta Boj; C Font; R Lecumberri; M Monreal; A J Muñoz Martín; R Otero; A Rubio; P Ruiz-Artacho; C Suarez Fernández; E Colome; P Pérez Segura Journal: Clin Transl Oncol Date: 2017-02-27 Impact factor: 3.405
Authors: Jan Beyer-Westendorf; Robert Klamroth; Stephan Kreher; Florian Langer; Axel Matzdorff; Hanno Riess Journal: Dtsch Arztebl Int Date: 2019-01-18 Impact factor: 5.594
Authors: Sake J van der Wall; Frederikus A Klok; Paul L den Exter; Deisy Barrios; Raquel Morillo; Suzanne C Cannegieter; David Jimenez; Menno V Huisman Journal: Hemasphere Date: 2018-02-02